86C Stock Overview
An agricultural technology company, discovers and develops novel biological products in Belgium and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Biotalys NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.92 |
| 52 Week High | €4.95 |
| 52 Week Low | €1.65 |
| Beta | 0.93 |
| 11 Month Change | -8.75% |
| 3 Month Change | 2.10% |
| 1 Year Change | 21.16% |
| 33 Year Change | -59.56% |
| 5 Year Change | n/a |
| Change since IPO | -60.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 86C | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -2.0% | -1.6% | -0.5% |
| 1Y | 21.2% | -1.0% | 8.3% |
Return vs Industry: 86C exceeded the German Chemicals industry which returned -1% over the past year.
Return vs Market: 86C exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| 86C volatility | |
|---|---|
| 86C Average Weekly Movement | 5.0% |
| Chemicals Industry Average Movement | 4.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 86C has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 86C's weekly volatility has decreased from 16% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 75 | Kevin Helash | www.biotalys.com |
Biotalys NV, an agricultural technology company, discovers and develops novel biological products in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and anthracnose in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; and BIOFUN-4 targeting oomycetes in fruits and vegetables.
Biotalys NV Fundamentals Summary
| 86C fundamental statistics | |
|---|---|
| Market cap | €110.13m |
| Earnings (TTM) | -€16.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.7x
P/E RatioIs 86C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 86C income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €16.34m |
| Earnings | -€16.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 21, 2025
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 13.7% |
How did 86C perform over the long term?
See historical performance and comparison